IRADIMED CORPORATION IRMD R2K
Healthcare · Medical Devices · United States
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible intravenous infusion pump systems and MRI compatible patient vital signs monitoring systems and related accessories. The company offers MRidium 3870 and 3860+ MRI Compatible IV Infusion Pump System with associated disposable IV tubing sets; 3880 MRI compatible patient vital signs monitoring system; and 3600 FMD1 with remote alarm logging unit ferromagnetic detection device. It also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. The company serves hospitals, acute care facilities, and outpatient imaging centers. It sells its products through direct field sales representatives, regional sales directors, clinical application specialists, and independent distributors in the United States and internationally. The company was incorporated in 1992 and is headquartered in Orlando, Florida.
READ MORE ›$90.66
+58.82% 1Y
Market & Price
Market Cap
$1.16B
Current Price
$90.66
High / Low (52W)
$104.87 / $55.42
Beta
0.91
Valuation
Stock P/E
49.54
Industry PE
23.65
Forward P/E
38.50
PEG Ratio
-
Book Value
$7.71
Price to Book
11.76
P/S
13.43
EV/EBITDA
37.53
Dividend Yield
0.88%
Profitability & Returns
ROCE
26.52%
ROE
25.04%
ROA
16.17%
Profit Margin
27.37%
Op Margin
32.93%
EPS (Latest Qtr)
$0.45
EPS (TTM)
$1.83
Balance Sheet & Liquidity
Debt/Equity
-
Quick Ratio
5.76
Current Ratio
7.13
Debt
$0
Total Assets
$108.78M
Current Assets
$81.20M
Working Capital
$71.02M
Ownership
Promoter Holding
35.22%
Chg in Prom Hold
-
FII / Inst Holding
61.02%
Chg in FII Hold
-
Financial Snapshot
Enterprise Value
$1.10B
Total Revenue (TTM)
$86.28M
EBITDA
$29.38M
Free Cash Flow
$15.16M
Operating Cash Flow
$28.95M
Shares Outstanding
12.78M
Gross Margin
76.83%
Payout Ratio
38.80%
Growth (CAGR)
Revenue 5Y
16.28%
Profit 5Y
20.56%
Revenue (YoY)
12.60%
Earnings (YoY)
22.10%
PROS
- Strong return on equity of 25.0%.
- Healthy ROCE of 26.5%.
- Excellent profit margin of 27.4%.
- Compounding revenue at 16.3% over 5 years.
- Profit CAGR of 20.6% over 5 years.
- Generates positive free cash flow.
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | IRMD IRADIMED CORPORATION R2K | 90.66 | 49.54 | $1.16B | 0.88% | 26.52% | 25.04% | 16.28% | 20.56% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Sep 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | 5.52M | 5.69M | 7.11M | 7.38M | 7.61M | 8.44M | 9.23M | 9.96M | 8.68M | 6.79M | 7.70M | 9.22M | 9.81M | 10.91M | 12.31M | 12.72M | 13.41M | 15.48M | 16.13M | 16.50M | 17.60M | 17.93M | 18.33M | - | 19.51M | 20.41M | 21.20M | 22.69M | 21.98M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.67M | 4.45M | 4.71M | 5.66M | 5.17M |
| Gross Profit | 1.81M | 2.90M | 3.83M | 2.85M | 5.66M | 6.19M | 6.60M | 7.26M | 8.13M | 6.27M | 3.77M | 4.29M | 4.38M | 5.42M | 5.67M | 5.79M | 6.39M | 7.37M | 7.80M | 6.46M | 4.93M | 5.74M | 7.06M | 7.33M | 8.41M | 9.38M | 10.14M | 10.54M | 11.72M | 12.19M | 12.84M | 13.39M | 14.01M | 14.19M | - | 14.84M | 15.95M | 16.49M | 17.03M | 16.81M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 9.41M | 9.17M | 9.66M | 9.94M | 9.58M |
| Operating Income | 355.84K | 824.08K | 1.61M | 406.31K | 2.26M | 2.69M | 3.20M | 3.48M | 3.34M | 2.59M | -238.38K | 327.57K | 196.06K | 1.09M | 1.68M | 1.45M | 1.51M | 2.38M | 2.52M | 737.24K | -2.93M | 784.76K | 1.78M | 1.84M | 3.09M | 3.07M | 4.17M | 4.13M | 4.01M | 4.96M | 5.91M | 4.75M | 5.63M | 5.79M | - | 5.43M | 6.79M | 6.83M | 7.09M | 7.24M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 5.63M | 7.00M | 7.22M | 7.47M | 7.69M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 5.95M | 7.33M | 7.30M | 7.79M | 7.77M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.26M | 1.55M | 1.72M | 1.35M | 1.95M |
| Net Income | 260.68K | 523.37K | 1.02M | 237.36K | 1.49M | 1.77M | 1.87M | 2.28M | 2.23M | 1.56M | -233.34K | 357.07K | 192.39K | 841.20K | 1.35M | 2.40M | 1.85M | 2.09M | 2.45M | 1.77M | -2.11M | 1.07M | 1.39M | 1.47M | 2.58M | 2.49M | 3.24M | 3.43M | 3.41M | 4.18M | 5.07M | 4.14M | 4.90M | 5.05M | - | 4.69M | 5.77M | 5.58M | 6.44M | 5.82M |
| Diluted EPS | 0.03 | 0.06 | 0.11 | 0.02 | 0.12 | 0.15 | 0.15 | 0.19 | 0.19 | 0.13 | -0.02 | 0.03 | 0.02 | 0.07 | 0.11 | 0.20 | 0.15 | 0.17 | 0.20 | 0.14 | -0.17 | 0.09 | 0.11 | 0.12 | 0.20 | 0.20 | 0.26 | 0.27 | 0.27 | 0.33 | 0.40 | 0.32 | 0.38 | 0.40 | - | 0.37 | 0.45 | 0.43 | 0.50 | 0.45 |
| R&D Expense | 299.42K | 224.30K | 225.50K | 303.46K | 342.30K | 403.45K | 518.56K | 234.34K | 291.82K | 457.13K | 541.29K | 449.01K | 382.70K | 379.83K | 395.99K | 373.58K | 352.57K | 331.31K | 369.53K | 430.28K | 482.65K | 476.88K | 475.82K | 453.68K | 480.70K | 519.10K | 662.60K | 491.64K | 3.00M | 961.95K | 452.56K | 821.00K | 801.13K | 639.47K | - | 624.00K | 877.36K | 674.36K | - | 956.00K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | 32.50M | 23.08M | 30.44M | 38.52M | 31.72M | - | 53.30M | 65.56M | 73.24M | 83.81M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | 12.02M | 15.40M | 16.89M | 19.49M |
| Gross Profit | 8.49M | 12.25M | 25.75M | 26.34M | 17.51M | 23.23M | 29.70M | 23.57M | - | 41.28M | 50.16M | 56.35M | 64.32M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | 25.65M | 30.12M | 34.38M | 38.18M |
| Operating Income | 2.79M | 3.07M | 11.51M | 10.92M | 1.29M | 6.00M | 8.65M | -756.09K | - | 15.63M | 20.04M | 21.96M | 26.15M |
| EBITDA | - | - | - | - | - | - | - | - | - | 16.30M | 20.80M | 22.78M | 27.31M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | 16.18M | 21.74M | 24.27M | 28.36M |
| Tax Provision | - | - | - | - | - | - | - | - | - | 3.35M | 4.55M | 5.04M | 5.88M |
| Net Income | 1.94M | 2.05M | 7.53M | 7.21M | 499.76K | 6.30M | 9.63M | 1.37M | - | 12.83M | 17.19M | 19.23M | 22.48M |
| Diluted EPS | 0.22 | 0.20 | 0.60 | 0.60 | 0.04 | 0.52 | 0.78 | 0.11 | - | 1.02 | 1.35 | 1.50 | 1.75 |
| R&D Expense | 1.01M | 1.07M | 1.76M | 1.35M | 1.72M | 1.52M | 1.43M | 1.90M | 1.91M | 2.28M | 2.86M | 2.83M | 2.98M |
Compounded Sales Growth
| 5 Years: | 16.28% |
| 1 Year: | 12.60% |
Compounded Profit Growth
| 5 Years: | 20.56% |
| 1 Year: | 22.10% |
Stock Price Performance
| 1 Year: | +58.82% |
| 6 Months: | -0.77% |
| 3 Months: | -12.23% |
| 1 Month: | +8.55% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 6.99M | 23.31M | 35.24M | 37.19M | 39.01M | 48.44M | 66.73M | 71.07M | - | 85.51M | 92.16M | 98.33M | 108.78M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | 77.49M | 76.00M | 75.24M | 81.20M |
| Cash & Equivalents | 1.70M | 2.46M | 9.45M | 19.37M | 17.71M | 18.21M | 28.03M | 43.48M | 50.07M | - | 57.96M | 49.76M | 52.23M | 51.16M |
| Inventory | - | - | - | - | - | - | - | - | - | - | 5.37M | 12.82M | 10.40M | 11.62M |
| Receivables | - | - | - | - | - | - | - | - | - | - | 13.27M | 12.22M | 10.56M | 13.67M |
| Total Liabilities | - | 1.56M | 2.42M | 3.31M | 5.31M | 6.08M | 6.50M | 11.20M | 9.68M | - | 11.84M | 20.74M | 11.51M | 14.16M |
| Current Liabilities | - | 1.45M | 2.28M | 2.89M | 3.66M | 4.08M | 4.69M | 5.86M | 4.92M | - | 8.55M | 16.33M | 8.51M | 10.18M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | - | - | - | 2.21M | 2.04M | 2.00K | 0 |
| Total Equity | 3.22M | 5.42M | 20.89M | 31.93M | 31.89M | 32.93M | 41.95M | 55.52M | 61.38M | - | 73.67M | 71.42M | 86.82M | 94.62M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | 12.59M | 12.66M | 12.71M | 12.78M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | 7.65M | 9.41M | 3.42M | 7.38M | 10.23M | 5.82M | - | 10.04M | 13.47M | 25.62M | 24.95M |
| Investing Cash Flow | -196.75K | -8.30M | -61.47K | -1.94M | -1.02M | 1.52M | 3.20M | 246.97K | - | -1.37M | -8.01M | -8.82M | -8.42M |
| Financing Cash Flow | - | - | 2.33M | -9.12M | -1.90M | 929.87K | 2.02M | 522.48K | - | -12.71M | -13.66M | -14.34M | -17.60M |
| Capital Expenditure | -163.18K | -583.98K | -298.72K | -780.81K | -775.57K | -228.31K | -368.28K | -443.00K | - | -1.87M | -8.01M | -8.82M | -8.42M |
| Free Cash Flow | - | - | 7.35M | 8.63M | 2.64M | 7.15M | 9.86M | 5.37M | - | 8.17M | 5.46M | 16.81M | 16.53M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | -4.04M | -8.20M | 2.47M | -1.07M |
| Share Buybacks | - | - | - | 9.97M | 1.82M | - | - | - | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - | - | - | - | - | 12.56M | 13.22M | 13.68M | 15.04M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | 81.1% | 75.9% | 76.3% | 77.1% | 74.3% | - | 77.4% | 76.5% | 76.9% | 76.7% |
| Operating Margin % | - | - | - | 33.6% | 5.6% | 19.7% | 22.5% | -2.4% | - | 29.3% | 30.6% | 30.0% | 31.2% |
| Net Margin % | - | - | - | 22.2% | 2.2% | 20.7% | 25.0% | 4.3% | - | 24.1% | 26.2% | 26.3% | 26.8% |
| ROE % | 35.7% | 9.8% | 23.6% | 22.6% | 1.5% | 15.0% | 17.3% | 2.2% | - | 17.4% | 24.1% | 22.2% | 23.8% |
| ROCE % | 50.4% | 14.6% | 35.6% | 32.6% | 3.7% | 13.7% | 14.2% | -1.1% | - | 20.3% | 26.4% | 24.5% | 26.5% |
Shareholding Pattern
Insiders
35.22%
Institutions
61.02%
Public Float
94.20%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 7.57% | 967.79K | $87.74M |
| 2 | Renaissance Technologies, LLC | 3.45% | 440.71K | $39.95M |
| 3 | Copeland Capital Management, LLC | 2.81% | 359.32K | $32.58M |
| 4 | Vanguard Capital Management LLC | 2.81% | 358.62K | $32.51M |
| 5 | Kayne Anderson Rudnick Investment Management LLC | 2.73% | 349.32K | $31.67M |
| 6 | Nine Ten Capital Management LLC | 2.62% | 334.49K | $30.32M |
| 7 | Geode Capital Management, LLC | 2.24% | 286.56K | $25.98M |
| 8 | T. Rowe Price Investment Management, Inc. | 2.01% | 256.70K | $23.27M |
| 9 | Dimensional Fund Advisors LP | 1.77% | 226.15K | $20.50M |
| 10 | State Street Corporation | 1.60% | 204.53K | $18.54M |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for IRMD
No recent headlines available.